Related Experiment Video
Updated: Apr 21, 2026
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
Development of assay platforms for in vitro screening of Treg modulating potential of pharmacological compounds
Anders Elm Pedersen1, Kim Holmstrøm, Flemming Jørgensen
1Department of International Health, Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark and.
Abstract:
CD4 + CD25+ regulatory T cells (Tregs) are believed to be pivotal in controlling chronic inflammation as well as in opposing the effect of cancer immunotherapy. Therefore, identification of novel drug compounds that interfere with Treg function is of high priority together with research that investigates Treg modulation by current drugs. For such research as well as for novel cell based therapies based on Treg infusions, rapid in vitro assays as well as functional assays based on inhibitory capacity of Tregs are required. Here, we report on such assays using highly pure fluorescence-activated cell sorting (FACS) sorted CD4 + CD25(high)CD127(dim/-)CD45RA+ naïve Treg cells followed by in vitro expansion. We report on the use of these cells in a short-term assay based on Treg mediated inhibition of the early effector T cell activation markers CD69 and CD154. Additionally, we investigate the use of highly pure Tregs in a functional assay based on Treg mediated inhibition of effector T cell proliferation. We report highly reproducible Treg function in assays that test the effect of well-known model compounds such as CpG-A, anti-IL-6R (tocilizumab), anti-TNF-α (adalimumab) or a combination of IL-6 and TNF-α. In conclusion, these assays have the potential for use in pharmacological screening and discovery in relation to drug development in immunology.
Insights
New assays enable rapid evaluation of regulatory T cell (Treg) function. These assays are crucial for developing drugs that modulate immune responses and for advancing Treg-based therapies.
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Regulatory T cells (Tregs) play a critical role in immune regulation, impacting chronic inflammation and cancer immunotherapy efficacy.
- There is a high demand for novel drug compounds that can modulate Treg function and for robust assays to study Treg activity.
- Existing methods for Treg analysis may not meet the requirements for rapid functional assessment needed for drug discovery and cell-based therapies.
Purpose of the Study:
- To develop and validate rapid in vitro assays for assessing the functional capacity of regulatory T cells (Tregs).
- To utilize these assays for the screening of drug compounds and the investigation of Treg modulation by existing therapeutics.
- To establish reliable methods for evaluating Treg-mediated inhibition of effector T cell activation and proliferation.
Main Methods:
- Isolation of highly pure CD4+CD25(high)CD127(dim/-)CD45RA+ naive Treg cells using fluorescence-activated cell sorting (FACS).
- In vitro expansion of isolated Tregs.
- Short-term assay measuring Treg-mediated inhibition of effector T cell activation markers (CD69, CD154).
- Functional assay assessing Treg-mediated inhibition of effector T cell proliferation.
- Testing the assays' reproducibility using known compounds like CpG-A, tocilizumab (anti-IL-6R), and adalimumab (anti-TNF-α).
Main Results:
- Successfully established and validated rapid in vitro assays for Treg function using FACS-sorted naive Tregs.
- Demonstrated reproducible Treg-mediated inhibition of effector T cell activation and proliferation in the developed assays.
- Showcased the utility of the assays in evaluating the effects of established immunomodulatory agents (CpG-A, anti-IL-6R, anti-TNF-α).
Conclusions:
- The developed assays provide a reliable and reproducible platform for assessing Treg function.
- These assays have significant potential for pharmacological screening and drug discovery in the field of immunology.
- The methodology supports research into Treg modulation for both therapeutic development and understanding immune responses.
